Literature DB >> 9611906

Cost-effectiveness of cardiovascular prevention programs in Spain.

P Plans-Rubió1.   

Abstract

Individual programs for prevention of cardiovascular disease include dietary and drug treatment of hypercholesterolemia, hypertension treatment, and smoking cessation therapies. In this study, the cost-effectiveness of available cardiovascular prevention programs was assessed in Spain in terms of net cost per life-year gained (LYG). Cost-effectiveness ratios ranged from US $2,600 to $80,000 per LYG in men and from $4,500 to $230,000 per LYG in women. In men aged 40-59 years, the ranking of increasing cost-effectiveness was: smoking cessation ($2,608-3,738 per LYG); treatment of moderate and severe hypertension ($8,564-38,678 per LYG); treatment of mild hypertension ($11,906-59,840 per LYG); dietary treatment ($16,143-20,158 per LYG); and drug treatment of hypercholesterolemia ($33,850-81,010 per LYG). In women, the ranking list was:smoking cessation ($4,482-5,756 per LYG), treatment of moderate and severe hypertension ($9,585-57,983 per LYG), treatment of mild hypertension ($15,248-86,075 per LYG), dietary treatment ($57,175-62,154 per LYG); and drug treatment of hypercholesterolemia ($104,100-259,150 per LYG).

Entities:  

Mesh:

Year:  1998        PMID: 9611906     DOI: 10.1017/s0266462300012289

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  7 in total

1.  Coverage of smoking cessation treatment by union health and welfare funds.

Authors:  E M Barbeau; Y I Li; G Sorensen; K M Conlan; R Youngstrom; K Emmons
Journal:  Am J Public Health       Date:  2001-09       Impact factor: 9.308

Review 2.  Economic evaluations of cholesterol-lowering drugs: a critical and systematic review.

Authors:  Pearl D Gumbs; Monique W M Verschuren; Aukje K Mantel-Teeuwisse; Ardine G de Wit; Anthonius de Boer; Olaf H Klungel
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  [Proposals for the appropriate organisation of smoking-dependence care and financing its pharmacological treatment].

Authors:  Javier Mataix Sancho
Journal:  Aten Primaria       Date:  2008-08       Impact factor: 1.137

Review 4.  The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications.

Authors:  José Manuel Rodríguez Barrios; Ferran Pérez Alcántara; Carlos Crespo Palomo; Paloma González García; Enrique Antón De Las Heras; Max Brosa Riestra
Journal:  Eur J Health Econ       Date:  2011-06-10

5.  Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.

Authors:  J M Gil; C Rubio-Terrés; A Del Castillo; P González; F Canorea
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405

6.  [Theoretical model of a cost-effectiveness analysis of combined enalapril-nitrendipine therapy for treating hypertension].

Authors:  F Antoñanzas; M Velasco; I Abbas; C Pontes; J Delgadillo; M Terán
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

7.  Allocation of resources between smoking cessation methods and lovastatin treatment of hypercholesterolaemia: based on cost effectiveness and the social welfare function.

Authors:  Pedro Plans-Rubió
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.